CClinicalTrials.gg
TerminatedNCT00491751Updated Jul 27, 2018Results posted

Clinical Utility of Endothelial Dysfunction in PAD

A Phase 1 interventional study of atorvastatin and ascorbic acid in Peripheral Arterial Disease, sponsored by Boston University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-27.

Sponsored by Boston University · Phase 1, Interventional, and Diagnostic

Why this study was terminated
Insufficient enrollment
Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will seek to determine whether non-invasive measures of endothelial function have utility as surrogate markers of cardiovascular risk in patients with peripheral arterial disease undergoing vascular surgery. Measurements of endothelial function will be made before and after initiation of atorvastatin, ascorbic acid, or placebo therapy during the pre-operative period. We will then examine cardiovascular events following surgery. We hypothesize that patients who have no improvement in endothelial function will have increased cardiovascular risk compared to patients with improvement in endothelial function.

Read the detailed description

Part 1 of the study will involve only patients with PAD who are undergoing non-cardiac surgery and is an intervention study. Part 2 will involve patients with PAD who have participated in Part 1 and patients with PAD who are not undergoing surgery. This part of the study does not involve an intervention.

The protocol for patients undergoing surgery is as follows: Part 1. Intervention study with follow-up for 30 days after surgery. Patients with planned surgery will be enrolled. We will test endothelial function at baseline using ultrasound and tonometry. They will then be randomzied to one of three groups: Atorvastatin 80 mg/d, Vitamin C 500 mg/d, or placebo. Subjects already on a statin medication at the time of enrollment will receive 40 mg/d of atorvastatin. Patients taking high dose statin (>40 mg/day) will be randomized to received vitamin C or placebo, and will not be eligible to receive any additional statin as part of the study. In the week immediately prior to surgery, we will test endothelial function a second time. They will then be followed for 30 days beginning with the day of surgery for cardiovascular events. Part 1 of the study involves 4 visits as follows: Visit 1 at enrollment will take place within 7-30 days of non-emergent vascular surgery and will last approximately 60 minutes Visit 2 will take place within approximately 1 week of surgery and will last approximately 30-40 minutes Visit 3 will occur on the 1st post-operative day and will last approximately 10-15 minutes Visit 4 will take place only if the subject is still an in-patient. It will take approximately 10-15 minutes Telephone contact will occur at 30 days post surgery and every six months thereafter for two years. The duration of telephone follow-up is expected to be approximately 5-10 minutes. Part 2 (long term follow-up): Patients who have completed Part 1 will be continued on in Part 2 of the study. Part 2 involves two year follow-up with no study medication. Telephone contact will be made every 6 months. subjects will make a visit to our research unit one year after the initial visit for physical examination, and if applicable, an ultrasound study of their bypass grafts.

The protocol for patients with PAD who are not undergoing surgery is as follows. These patients will participate in Part 2 of the study only (long-term follow-up with no intervention). Visit 1: will last approximately 60 minutes and involve measurement of endothelial function by ultrasound and tonometry. We will contact the subject every 6 months by telephone (5-10 minutes) for two years to determine whether a cardiovascular event has occurred. Visit 2 will occur at 1 year post enrollment and will last approximately 20-30 minutes. If the subject has had peripheral bypass surgery, we will perform an ultrasound study to determine graft blood flow.

02

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • endothelium
  • nitric oxide
  • statins
  • ascorbic acid
03

In context

Peripheral Arterial Disease

1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.

This study's enrollment of 108 is above the median of 74 across 1,066 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Boston University is the lead sponsor of 266 studies on the registry; 37 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 24 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male and female subjects age 21-99 years old.
  2. Peripheral Arterial Disease. PAD is defined clinically and by angiography, magnetic resonance imaging, vascular ultrasound, or ankle brachial index less than 0.9.
  3. Able to provide informed consent and complete the study procedure.
  4. Patients undergoing non-emergent vascular surgery (peripheral arterial bypass, abdominal aortic aneurysm repair, carotid endarterectomy, or limb amputation) or other non-cardiac surgery.

Exclusion criteria

Exclusion Criteria:

  1. Emergent or urgent surgery that must be performed sooner than one week after enrollment
  2. Unstable angina, myocardial infarction, stroke, coronary revascularization, or decompensated heart failure within 1 month of enrollment. Patients who require cardiac catheterization and surgical or percutaneous coronary revascularization prior to vascular surgery will be excluded.
  3. Clinically evident major illness of other organ systems, including cancer, end-stage renal disease, hepatic failure, or other conditions that make participation inappropriate.
  4. Women who are lactating, pregnant, or of childbearing potential and not using a reliable contraceptive method. Pregnancy will be excluded by a urine pregnancy test.
  5. Patients with liver function tests or serum creatine kinase >3 times the upper limit of normal.
  6. Patients who have received an investigational drug within 30 days of enrollment.
  7. Patients or subjects with a history of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
  8. Known occlusive atherosclerosis of the subclavian artery or upper extremity, because such disease will interfere with induction of reactive hyperemia during the brachial artery ultrasound studies.
  9. Patients will be excluded if they are taking vitamin C in a dose greater than 2 times the Recommended Daily Allowance (>120 mg/day) within 1 month of enrollment.
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Atorvastatin

    Atorvastatin 40 or 80 mg/day

    Drug: atorvastatin

  • Experimental
    Ascorbic Acid

    Ascorbic Acid 500 mg/day

    Drug: ascorbic acid

  • Placebo comparator
    Placebo

    Placebo atorvastatin and Placebo ascorbic acid

    Drug: Placebo

Interventions

  • Drugatorvastatin

    atorvastatin 40 or 80 mg/day

    Also known as: Lipitor

  • Drugascorbic acid

    ascorbic acid 500 mg/day

    Also known as: Vitamin C

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Change in FMD

    Change in flow mediated dilation with treatment: FMD visit 2 - FMD visit 1 FMD is measured by using vascular ultrasound to determine the baseline diameter of the brachial artery. Endothelium-dependent vasodilation is induced by 5-minute arterial occlusion with a blood pressure cuff. When the cuff is released, the resultant increase in blood flow (reactive hyperemia) stimulates vasodilation of the brachial artery. This flow-mediated dilation (FMD) is expressed as the percent change from baseline. Healthy individuals typical dysplay a 10 to 12% dilation. Individuals with PAD had markedly impaired dilation of 6-7. The currernt study sought to determine whether a change in FMD would occur following intervention.

    Time frame: 1-4 weeks

Secondary outcomes

  1. Percentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group)

    This outcome is independent of the treatment group so the groups are 'CVD event' and ' No CVD Event'. Cardiovascular events (CVD) included cardiovascular disease, myocardial infarction, congestive heart failure, stroke, and unstable angina.

    Time frame: 2 months

07

Results

Posted Jul 27, 2018
Limitations and caveats
The study was terminated after enrollment of 108 of 450 subjects due to inability to enroll a sufficient number of subjects. Enrollment was difficult because nearly all potential subjects were already taking a statin.

Participant flow

Recruitment: May 2004 to June 2010.

Participant flow — Overall Study
MilestoneAtorvastatinAscorbic AcidPlacebo
Started224442
Completed224442
Not completed000

Outcome measures

PrimaryChange in FMD

Change in flow mediated dilation with treatment: FMD visit 2 - FMD visit 1 FMD is measured by using vascular ultrasound to determine the baseline diameter of the brachial artery. Endothelium-dependent vasodilation is induced by 5-minute arterial occlusion with a blood pressure cuff. When the cuff is released, the resultant increase in blood flow (reactive hyperemia) stimulates vasodilation of the brachial artery. This flow-mediated dilation (FMD) is expressed as the percent change from baseline. Healthy individuals typical dysplay a 10 to 12% dilation. Individuals with PAD had markedly impaired dilation of 6-7. The currernt study sought to determine whether a change in FMD would occur following intervention.

Time frame:
1-4 weeks
Reported as:
Mean · percent change of FMD
Change in FMD
percent change of FMDAtorvastatinAscorbic AcidPlacebo
Change in FMD0.88 ± 3.00.41 ± 3.60.88 ± 3.5
SecondaryPercentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group)

This outcome is independent of the treatment group so the groups are 'CVD event' and ' No CVD Event'. Cardiovascular events (CVD) included cardiovascular disease, myocardial infarction, congestive heart failure, stroke, and unstable angina.

Time frame:
2 months
Reported as:
Mean · percent change of flow-mediated dilation
Percentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group)
percent change of flow-mediated dilationCVD EventNo CVD Event
Percentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group)0.5 ± 4.00.7 ± 3.4

Adverse events

Collected over 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin0/22 (0%)3/22 (13.6%)0/22 (0%)
Ascorbic Acid1/44 (2.3%)6/44 (13.6%)0/44 (0%)
Placebo1/42 (2.4%)7/42 (16.7%)0/42 (0%)
Most frequent serious events
Most frequent serious events
EventAtorvastatinAscorbic AcidPlacebo
Myocardial infactionCardiac disorders2/222/446/42
CVA/TIANervous system disorders2/222/440/42
Unstable anginaCardiac disorders0/220/443/42
Other CVD eventCardiac disorders1/223/443/42
Congestive heart failureCardiac disorders0/222/442/42
Venticular fibrillationCardiac disorders0/220/441/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AtorvastatinAscorbic AcidPlaceboTotal
<=18 years0000
Between 18 and 65 years11222154
>=65 years11222154
Age, Continuous
Age, Continuous(years)AtorvastatinAscorbic AcidPlaceboTotal
Mean68 ± 1166 ± 865 ± 966 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)AtorvastatinAscorbic AcidPlaceboTotal
Female914629
Male13303679
Region of Enrollment
Region of Enrollment(participants)AtorvastatinAscorbic AcidPlaceboTotal
United States224442108
08

Study locations

1 site
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00491751
Lead sponsor
Boston University
Responsible party
Sponsor
First posted
Jun 26, 2007
Start date
May 2004
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jul 27, 2018
Last update
Jul 27, 2018

Study contacts

Naomi Hamburg, MD
principal investigator · Boston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion